Objective: To evaluate inflammatory, oxidizing, and reducing responses during the progression of type 1 diabetes mellitus (T1DM) in patients without chronic complications. Subjects and methods: Plasma antioxidant status, reactive oxygen species (ROS), and interleukin-6 (IL-6) were measured in 42 patients with T1DM and in 24 healthy subjects. Results: Significant increases were detected in the median values of ROS and IL-6 in patients with T1DM compared with healthy subjects (ROS ~ 4,836 vs. 2,036 RLU/min, respectively; P < .05: IL-6 ~ 14.2 vs. 9.7 pg/mL, respectively; P = .002). No significant between-group differences (P > 0.05) were observed in oxidizing responses or in IL-6 concentrations when diabetic patients were grouped according to time after diagnosis (0 -10, 10 -20 and > 20 years). Plasma antioxidant responses were similar in patients with T1DM and in healthy subjects. Conclusions: Our results demonstrate that oxidizing and inflammatory responses are increased at the onset of T1DM, but remain unchanged during disease progression. These findings suggest that functional changes involved in diabetic complications may commence in the first years after diagnosis. Arq Bras Endocrinol Metab.
INTRODUCTION
T ype 1 diabetes mellitus (T1DM) is an inflammatory disease of the pancreatic islets in which the destruc tion of beta cells is mediated by cytotoxic T cells, self antibodies, and inflammatory mediators (1) . High le vels of inflammatory biomarkers can be detected in pa tients that have been recently diagnosed with T1DM, and this indicates that the inflammatory response is ac tivated during very early stages of the disease (2, 3) .
It has been suggested that a number of different hyperglycemiainduced biochemical mechanisms may be involved in the pathogenesis of complications that are characteristic of diabetes. In this context, it is known that hyperglycemia is linked with the activation of protein kinase C (PKC) and nuclear factor kappa B, enhanced polyol activity, increased formation of advanced glyca tion endproducts (AGEs), and elevated flux through the hexosamine pathway (4, 5) . A mechanism that is common to all the pathways implicated in these oxidati ve processes involves the generation of reactive oxygen species (ROS) (6) , which lead to changes in blood flow, vascular permeability, and angiogenesis. Increased levels of ROS stimulate PKC via diacylglycerol (DAG), and give rise to greater production of inflammatory cytoki nes, mainly interleukin6 (IL6), which is considered the primary mediator of acute inflammatory response. Ho wever, all inflammatory cytokines exhibit cytotoxic and cytostatic activities and have the ability to induce apop tosis in pancreatic islet cells (7) . It has been hypothesized that alterations in oxidative metabolism without simulta neous increases in antioxidant response are characteristic of oxidative stress which, in endothelial cells, results in endothelial dysfunction and vascular damage (4, 6) .
Over the last few decades, studies on atherosclerosis and other inflammatory disorders have shown that le vels of inflammatory markers can be used to predict car diovascular risk, thus reinforcing the need to define the impact of inflammatory activity in diabetes (8) . While the main determinants of tissue injury in diabetes are believed to be the duration and severity of hyperglyce mia (9) , there are very few reports on the changes that occur in inflammatory, oxidizing, and reducing respon ses during the progression of T1DM. Several authors have stated that, in patients with T1DM, no significant pathological consequences of diabetes can be detected earlier than 5 years from onset (10), even though sig nificant increases in ROS generation can be detected in patients at the onset of the disease (11) . These findings suggest that the structural and functional changes in volved in diabetic complications may commence at the onset of the hyperglycemic trigger, and it is possible that, in the presence of persistent acute peaks or chro nic hyperglycemia, inflammatory metabolic and immu nological pathways can become activated at all times after diagnosis (12) .
In the light of the information presented above, the objective of the present study was to investigate inflam matory and antioxidant status in patients with T1DM but without chronic complications, during the first years after diagnosis (010 years) and during further progres sion of the disease (1020 and > 20 years after diagnosis).
METHODS
Details of the study were submitted to, and approved by the Ethical Committee of the Santa Casa Hospital in Belo Horizonte, Minas Gerais, Brazil. The investiga tion was conducted according to the principles of the Declaration of Helsinki, and written informed consent was obtained from each participant before the study.
Subjects
The study population was made of 42 patients with T1DM and 24 healthy subjects. Diabetic patients exhi biting micro or macrovascular complications or ketoa cidosis in the previous year, and those who were taking statin and/or metformin and/or vitamins, or suffering from infection, dementia, inflammation, or malignant disease, or addicted to smoking or alcohol, or were pregnant, were excluded from the study. Patients with T1DM who were selected to be included in the study showed clinical onset of the disease 13.03 ± 9.42 years before, and presented history of diabetic ketoacidosis and/or were positive for glutamic acid dehydrogenase (GAD) antibodies and C peptide (< 0.5 ng/mL). The patients selected for the study, all of whom were recei ving intensive insulin therapy by means of multiple dai ly injections, were divided into three groups according to the time elapsed since diagnosis, namely, 010 years, 1020 years, and > 20 years. Clinical and biochemical evaluations were performed in all participants accor ding to standard procedures.
heparinized venous blood (10.0 mL), and was stored at −20°C until the moment of analysis. Granulocytes were purified using a FicollHypaque gradient according to the method described by Bicalho and cols. (13) .
Estimation of ROS production in granulocytes
Luminometric determination of the modulation of gra nulocyte ROS generation was carried out using a quan titative chemiluminescence assay. Granulocytes (1 x 10 6 cells/mL; 200 μL) suspended in phosphate buffered saline (PBS; 300 μL) were transferred to an unsealed luminescence tube together with luminol (200 μL) dis solved in 0.4 M dimethyl sulfoxide. Chemiluminescen ce of the assay mixture was monitored for 30 min. After that, ROS production was stimulated by the addition of a 10μL aliquot of 10 4 M phorbol 12,13dibutyrate (PDB), and chemiluminescence monitored for other 30 min (13) . Results of the assay were expressed in re lative light units (RLU) per minute.
Evaluation of plasma antioxidant status
Plasma antioxidant status was determined from the direct reduction of 3(4,5dimethylthiazol2yl)2,5 diphenyltetrazolium bromide (MTT; Sigma Chemi cal Co.) according to the method of Medina and cols. (14) . Briefly, a 200μL aliquot of plasma was mixed with 25 μL of MTT solution (5.0 mg/mL in PBS), the final volume was adjusted to 500 μL with PBS, and the whole mixture was incubated for 120 min at 37°C. The reaction was subsequently terminated by the addition of 1.0 mL of 0.04 M hydrochloric acid in isopropanol. The mixture was centrifuged (200 g, 10 min) and ab sorbance of the supernatant measured at 570 nm.
Determination of IL-6
Plasma concentrations of IL6 were determined by en zymelinked immunosorbent assay (ELISA) using As say Designs (Enzo Life Sciences) Human IL6 Enzyme Immunometric kits.
Statistical analyses
The ShapiroWilk test was applied in order to verify that data were normally distributed and, where applica ble, mean values were compared using Student's ttests for paired samples. Betweengroup comparisons of me dian values of inflammatory biomarkers and plasma re ducing responses of diabetic patients were performed using the nonparametric MannWhitney test. Within group correlations were determined using Spearman rank correlation tests. In all cases, statistical significance was accepted at P values < 0.05.
RESULTS

Baseline characteristics of the study populations
Clinical characteristics of patients with T1DM and heal thy subjects were very similar, as shown in Table 1 . In relation to biochemical characteristics, fasting plasma glucose values were significantly increased in diabetic patients in comparison with healthy subjects (P < .05), while levels of glycated hemoglobin (HbA1c) in patients with T1DM (8.84%) were somewhat higher than the accepted range for healthy subjects (< 7%). When clini cal and biochemical characteristics of the population of diabetic patients were distributed according to the time elapsed since diagnosis (Table 2 ), significant between group differences were observed in some parameters, although these were not significant in clinical practice.
Inflammatory biomarkers and oxidative stress
A significant difference was detected between patients with T1MD and healthy subjects in relation to the me dian values of ROS production in unstimulated granu locytes (4,836 versus 2,036 RLU/min, respectively; P < 0.05) ( Figure 1A ). The presence of phorbol ester stimulated granulocyte ROS production differently in diabetic patients and healthy subjects (22369 and 5780 RLU/min, respectively; P < 0.05) ( Figure 1B ). Addi tionally, IL6 plasma levels of patients with T1MD were significantly higher than those of healthy subjects (14.2 versus 9.7 pg/mL, respectively; P = 0.002) ( Figure 1C ). In contrast, no significant difference (P > 0.05) was ob served between diabetic patients and healthy subjects in relation to plasma reducing responses (as determined by direct reduction of MTT), although patients with T1DM showed a slightly lower response (median va lues 0.3 versus 0.29 OD 570 ) ( Figure 1D ).
When the levels of inflammatory biomarkers and plasma reducing responses determined in patients with T1DM were distributed according to time elapsed sin ce diagnosis, no significant betweengroup differences (P > 0.05) were detected (Figures 2AC). However, values of the inflammatory markers of the three groups of time elapsed since diagnosis, when considered indivi dually, were significantly different from the correspon Table 2 . Clinical and biochemical characteristics of patients with T1DM stratified according to time elapsed after diagnosis Correlations of parameters within the groups of diabetic patients
There were no significant correlations between the levels of inflammatory biomarkers in the diabetic pa tients, either considered as a single group or when divi ded according to time since diagnosis, or between the se markers and the clinical and biochemical parameters evaluated. Similar results were observed in relation to plasma antioxidant status. Additionally, there were no correlations between fasting glucose, HbA1c and in flammatory biomarkers or plasma antioxidant status.
DISCUSSION
Results obtained in the present study suggest the pre sence of systemic inflammation in diabetic patients at all moments after T1DM diagnosis. Such condition results from an increased oxidizing metabolic response in the absence of compensating increase in plasma antioxidant status, and is indicative of oxidative stress at disease on set and in longestablished T1DM. A considerable body of evidence has been accumula ted over the last few decades supporting the hypothesis that ROS generation, and the resultant oxidative stress, plays a central role in the pathogenesis of diabetic com plications. In this context, it is welldocumented that pathways stimulated by hyperglycemia (i.e., glucose oxidation, enhanced polyol pathway activity, and for mation of complexes between AGEs and their recep tors) bring about cell injury in response to oxidative stress (15) . In addition, ROS triggers an inflammatory cascade by means of the production of proinflamma tory cytokines, such as IL6, which are involved in the pathogenesis of micro and macrovascular complica tions. Indeed, these signaling cytokines are often em ployed as markers of the inflammatory response (16) .
Studies focusing on the extent of free radical forma tion in diabetic patients are scarce because of the inhe rent difficulties involved in measuring low concentra tions of such highly reactivity and shortlived species in body fluids. Instead, surrogate markers are commonly employed in order to evaluate oxidative stress. In the present study, ROS production by granulocytes from patients with T1DM was significantly higher than in healthy subjects. This result is in accordance with that of Reis and cols. (11) who reported levels of ROS that were significantly elevated in 16 young patients with T1DM (age, 15.25 ± 3.83 years; duration of disease, 2.62 ± 2.24 years; HbA1c, 10.18 ± 2.5%) in compari son with their healthy counterparts. Ceriello and cols. (17) were able to demonstrate a significant increase in the production of superoxide anions (SOA) in 10 patients with T1DM, although the study was limited to adult subjects. On the other hand, Hsu and cols. (18) analyzed a group of 47 diabetic children (age, 12.7 ± 4.8 years; duration of disease, 4.94 ± 3.28 years; HbA1c, 9.22 ± 2.63%), and reported significantly hi gher levels of SOA compared with healthy individuals.
Increased levels of diacylglycerol (DAG) and the activation of PKC induced by hyperglycemia have also been associated with the initiation of diabetic complica tions. Phorbol esters are analogues of DAG and mimic the in vitro hyperglycemia effect of the glyceride by me ans of direct stimulation of PKC. In the present study, ROS generation in the presence of phorbol ester was increased both in patients with T1DM and in healthy subjects, but the enhancement was much more intense in diabetic patients (Figure 1 ). This suggests that hyper glycemia activates the expression of membrane PKC.
A significant increase in IL6 levels between diabetic patients and healthy subjects was detected in the pre sent study. This finding is consistent with other reports of significant increases in the concentration of IL6 in patients with T1DM, but without microor macrovas cular complications, in comparison with healthy indivi duals (19, 20) . Similarly, a recent SEARCH study (21) focusing on the association of between inflammation and obesity, dyslipidemia, and hyperglycemia in 553 young patients with T1DM, and 215 healthy indivi duals, found significantly higher levels of IL6 in the diabetic group irrespective of weight or HbA1c con centration. In contrast, Erbagci and cols. (22) and Alexandraki and cols. (3) reported that there were no differences in IL6 levels between children and adults with T1DM and their healthy counterparts.
The present study revealed no significant differences in the levels of inflammatory biomarkers between dia betic patients grouped according to progression of the disease (i.e., 010 years, 1020 years, and > 20 years af ter diagnosis). However, when these groups were con sidered either individually or as a whole, such markers were significantly higher than in healthy subjects. The division by time elapsed after diagnosis is somewhat ar bitrary, given that T1DM frequently lasts more than 5 years, and there is no literature studies that have eva luated inflammatory biomarkers in the intervals used in the present study. Because of this, it is not possible to draw a direct comparison of the present results with Arq Bras Endocrinol Metab. 2012;56/7 previously reported ones. However, Hsu and cols. (18) detected no significant differences between groups of children with T1DM when concentrations of SAO were compared in relation to disease duration (< 5 years versus > 5 years), even though levels of the biomarker were significantly higher in the diabetic children (grouped together) compared with healthy children. Erbagci and cols. (22) observed no differences in the levels of IL6 between healthy children and those with T1DM, but when the diabetic children were divided according to time after diagnosis, IL6 levels were higher in recen tly diagnosed (< 1 year) patients compared with long standing (> 1 year) patients. In contrast, the SEARCH study found no differences in IL6 concentrations be tween young patients with T1DM when grouped ac cording to disease duration (< 1 year versus > 1 year after diagnosis) (21) .
In the present study, no significant differences in plasma antioxidant status were observed between he althy subjects and patients with T1DM (considered together or grouped according to time elapsed since diagnosis). However, results revealed a slight, but not significant, increase in antioxidant status in diabetic patients who had been diagnosed for > 20 years. This increase was not attributable to the use of drugs, since none of the patients studied was receiving any medica tion other than insulin. To the best of our knowledge, only one published study is available reporting antioxi dant concentrations (superoxide dismutase, glutathio ne peroxidase, glutathione reductase, and vitamins A, C, and E) in patients with T1DM grouped according to disease progression (< 5 years versus > 5 years after diagnosis), and it showed no betweengroup differen ces in the parameters (18) .
The present study revealed that inflammatory bio markers were not correlated with glycemic control (i.e., fasting glucose and HbA1c) or with any of the clinical and biochemical parameters studied. The possible cor relation between inflammatory biomarkers and glyce mic control is somewhat controversial. Acute hyper glycemia and poor glycemic control during the early stages of diabetes has been associated with increased inflammation in children with T1DM (3), but it is un clear whether chronic hyperglycemia, caused by long established diabetes, is associated with inflammation. Thus, according to a study of 22 children with T1DM, Rosa and cols. (23) reported that acute hyperglycemia was associated with increased levels of IL6, IL4, and IL1, and these elevated levels persisted for at least 2 h after glucose control. On the other hand, a number of studies have found no such associations (16, 24, 25) . The lack of correlation between inflammatory bioma rkers and levels of fasting glucose or HbA1c may sug gest that, once triggered, inflammatory response can be modulated positively or negatively by parameters other than those studied, including, for example, glucose excursions (12) . This hypothesis simply reinforces the complexity and multifactorial nature of T1DM.
The results obtained in the present study suggest that, during the first years after diagnosis of the disease, when the majority of patients do not present chronic complications, T1DM is characterized by a proinflam matory profile and absence of compensatory antioxidant response. However, this type of profile does not differ from that exhibited by patients with longestablished T1DM in whom micro and macrovascular complica tions are more prevalent. In other words, typical oxi dative stress exists since early stages of the disease, and structural and functional changes involved in diabetic complications may start in the first years after diagnosis.
